Omega Therapeutics Ownership

OMGA
 Stock
  

USD 6.70  0.10  1.47%   

Some institutional investors establish a significant position in stocks such as Omega Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Omega Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Please check Your Equity Center.
  
Omega Therapeutics owns a total of fourty-seven million seven hundred seventy thousand outstanding shares. The majority of Omega Therapeutics outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Omega Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Omega Therapeutics. Please pay attention to any change in the institutional holdings of Omega Therapeutics as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.

Omega Stock Ownership Analysis

About 89.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.47. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Omega Therapeutics recorded a loss per share of 5.03. The entity had not issued any dividends in recent years. Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Omega Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 79 people. To find out more about Omega Therapeutics contact the company at 617 949 4360 or learn more at https://omegatherapeutics.com.

Omega Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Omega Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Omega Therapeutics backward and forwards among themselves. Omega Therapeutics' institutional investor refers to the entity that pools money to purchase Omega Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Wells Fargo CompanyCommon Shares51.00.0
Wells Fargo CompanyCommon Shares14.3 K89 K
Wells Fargo CompanyCommon Shares13.2 K150 K
Wells Fargo CompanyCommon Shares41.01000
Wade G W IncCommon Shares10 K38 K
Victory Capital Management IncCommon Shares102.3 K639 K
Victory Capital Management IncCommon Shares109.4 K1.2 M
Note, although Omega Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Omega Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Omega Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Omega Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Omega Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Karande Mahesh over three weeks ago via Macroaxis 
Acquisition by Karande Mahesh of 170000 shares of Omega Therapeutics subject to Rule 16b-3
Young Richard A over two months ago via Macroaxis 
Sale by Young Richard A of 10000 shares of Omega Therapeutics
Boehm Rainer J over two months ago via Macroaxis 
Acquisition by Boehm Rainer J of 36713 shares of Omega Therapeutics subject to Rule 16b-3
Levy Elliott M over three months ago via Macroaxis 
Acquisition by Levy Elliott M of 18118 shares of Omega Therapeutics subject to Rule 16b-3
Mcmanus Kevin over six months ago via Macroaxis 
Acquisition by Mcmanus Kevin of 125000 shares of Omega Therapeutics subject to Rule 16b-3
Karande Mahesh over six months ago via Macroaxis 
Acquisition by Karande Mahesh of 340000 shares of Omega Therapeutics subject to Rule 16b-3
Karande Mahesh over six months ago via Macroaxis 
Exercise or conversion by Karande Mahesh of 11300 shares of Omega Therapeutics subject to Rule 16b-3
Moore Yan over six months ago via Macroaxis 
Acquisition by Moore Yan of 477715 shares of Omega Therapeutics subject to Rule 16b-3
Flagship Pioneering Inc over a year ago via Macroaxis 
Omega Therapeutics exotic insider transaction detected
Flagship Pioneering Inc over a year ago via Macroaxis 
Conversion by Flagship Pioneering Inc of 1666666 shares of Omega Therapeutics
Sawhney Roger over a year ago via Macroaxis 
Purchase by Sawhney Roger of 2941 shares of Omega Therapeutics
Afeyan Noubar over a year ago via Macroaxis 
Acquisition by Afeyan Noubar of 19852 shares of Omega Therapeutics subject to Rule 16b-3

Be your own money manager

Our tools can tell you how much better you can do entering a position in Omega Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Global Markets Map Now

   

Global Markets Map

Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Omega Therapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Your Equity Center. Note that the Omega Therapeutics information on this page should be used as a complementary analysis to other Omega Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for Omega Stock analysis

When running Omega Therapeutics price analysis, check to measure Omega Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Omega Therapeutics is operating at the current time. Most of Omega Therapeutics' value examination focuses on studying past and present price action to predict the probability of Omega Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Omega Therapeutics' price. Additionally, you may evaluate how the addition of Omega Therapeutics to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Omega Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omega Therapeutics. If investors know Omega will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omega Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
321.9 M
Return On Assets
(0.28) 
Return On Equity
(0.52) 
The market value of Omega Therapeutics is measured differently than its book value, which is the value of Omega that is recorded on the company's balance sheet. Investors also form their own opinion of Omega Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Omega Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omega Therapeutics' market value can be influenced by many factors that don't directly affect Omega Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Omega Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Omega Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omega Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.